Hinge Health pops 17%, but joins growing ranks of down round IPOs

Digital physical therapy company Hinge Health's stock closed up 17% at $37.56 on its first day of trading on the NYSE, pricing its IPO at $32 and raising $437 million. However, its approximate market capitalization of $3 billion is less than half of its $6.2 billion valuation from its 2021 Series E funding round led by Tiger Global, reflecting a trend of companies accepting lower IPO valuations compared to peak private valuations from 2020-2021; Omada Health, a competitor in the digital health space, has also filed to go public.

Analysis

Hinge Health's initial public offering saw its shares close at $37.56, a 17% increase over its $32 IPO price, indicating positive initial market reception. Despite this first-day gain, the company's public market capitalization of approximately $3 billion is less than half its $6.2 billion valuation from its October 2021 Series E round, led by Tiger Global, highlighting a significant recalibration from peak private market valuations. This trend of "down-round IPOs" is becoming increasingly common, as evidenced by companies like Reddit and ServiceTitan, reflecting a normalization after the exuberant 2020-2021 funding environment and a lessened stigma for companies going public at valuations below prior private rounds. Hinge Health raised $437 million through its IPO, with $237 million in proceeds allocated directly to the company, to further its mission of reducing musculoskeletal pain via its digital physical therapy platform utilizing wearable sensors and computer vision. The competitive landscape includes Sword Health, valued at $3 billion approximately a year ago and reportedly considering a 2025 IPO, and Omada Health, another digital health competitor which recently filed to go public, underscoring continued investor interest and potential consolidation within the burgeoning digital health sector.

Key Decisions for Investors

• Acknowledge Hinge Health's 17% first-day trading gain but weigh this against the substantial valuation haircut of over 50% from its 2021 private round, suggesting a more cautious long-term valuation perspective is warranted.
• Closely monitor Hinge Health's deployment of the $237 million in net IPO proceeds for market expansion and product innovation, particularly its performance against direct competitors like Sword Health and the recently IPO-filing Omada Health.
• Recognize that the current market acceptance of 'down-round' IPOs, such as Hinge's, may signal more rational entry points for growth-oriented digital health companies, though thorough due diligence on post-IPO execution and competitive positioning remains critical.